A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma
Public ClinicalTrials.gov record NCT00452699. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects With Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of asthma control will provide key information on the efficacy and safety of the combination therapy. The safety measure will be an assessment of adverse events
Study identification
- NCT ID
- NCT00452699
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 621 participants
Conditions and interventions
Conditions
Interventions
- Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID Drug
- Fluticasone propionate 250 mcg BID Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2007
- Primary completion
- Apr 30, 2009
- Completion
- Apr 30, 2009
- Last update posted
- Dec 7, 2016
2007 – 2009
United States locations
- U.S. sites
- 58
- U.S. states
- 26
- U.S. cities
- 51
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Scottsdale | Arizona | 85251 | — |
| GSK Investigational Site | Little Rock | Arkansas | 72205 | — |
| GSK Investigational Site | Fountain Valley | California | 92708 | — |
| GSK Investigational Site | Los Angeles | California | 90095-1690 | — |
| GSK Investigational Site | Rancho Mirage | California | 92270 | — |
| GSK Investigational Site | Riverside | California | 92506 | — |
| GSK Investigational Site | San Jose | California | 95117 | — |
| GSK Investigational Site | Denver | Colorado | 80206 | — |
| GSK Investigational Site | Denver | Colorado | 80230 | — |
| GSK Investigational Site | Fort Collins | Colorado | 80526 | — |
| GSK Investigational Site | Fort Collins | Colorado | 80528 | — |
| GSK Investigational Site | Stamford | Connecticut | 06902 | — |
| GSK Investigational Site | Coral Gables | Florida | 33134 | — |
| GSK Investigational Site | Miami | Florida | 33173 | — |
| GSK Investigational Site | Pensacola | Florida | 32504 | — |
| GSK Investigational Site | Tallahassee | Florida | 32308 | — |
| GSK Investigational Site | Tamarac | Florida | 33321 | — |
| GSK Investigational Site | Columbus | Georgia | 31904 | — |
| GSK Investigational Site | Conyers | Georgia | 30013 | — |
| GSK Investigational Site | Lilburn | Georgia | 30047 | — |
| GSK Investigational Site | South Bend | Indiana | 46617 | — |
| GSK Investigational Site | Metairie | Louisiana | 70006 | — |
| GSK Investigational Site | Bethesda | Maryland | 20814 | — |
| GSK Investigational Site | Wheaton | Maryland | 20902 | — |
| GSK Investigational Site | Ypsilanti | Michigan | 48197 | — |
| GSK Investigational Site | St Louis | Missouri | 63104 | — |
| GSK Investigational Site | Billings | Montana | 59102 | — |
| GSK Investigational Site | Bozeman | Montana | 59718 | — |
| GSK Investigational Site | Omaha | Nebraska | 68130 | — |
| GSK Investigational Site | Cherry Hill | New Jersey | 08003 | — |
| GSK Investigational Site | Great Neck | New York | 11023 | — |
| GSK Investigational Site | New York | New York | 10021 | — |
| GSK Investigational Site | Utica | New York | 13502 | — |
| GSK Investigational Site | Asheville | North Carolina | 28801 | — |
| GSK Investigational Site | High Point | North Carolina | 27262 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45231 | — |
| GSK Investigational Site | Portland | Oregon | 97213 | — |
| GSK Investigational Site | Tigard | Oregon | 97223 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15241 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15243 | — |
| GSK Investigational Site | East Providence | Rhode Island | 02914 | — |
| GSK Investigational Site | Providence | Rhode Island | 02906 | — |
| GSK Investigational Site | Providence | Rhode Island | 02909 | — |
| GSK Investigational Site | Gaffney | South Carolina | 29340 | — |
| GSK Investigational Site | Orangeburg | South Carolina | 29118 | — |
| GSK Investigational Site | Spartanburg | South Carolina | 29303 | — |
| GSK Investigational Site | Union | South Carolina | 29309 | — |
| GSK Investigational Site | Austin | Texas | 78750 | — |
| GSK Investigational Site | Corsicana | Texas | 75110 | — |
| GSK Investigational Site | El Paso | Texas | 79925 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | Houston | Texas | 77054 | — |
| GSK Investigational Site | Richmond | Virginia | 23225 | — |
| GSK Investigational Site | Richmond | Virginia | 23229 | — |
| GSK Investigational Site | Olympia | Washington | 98506 | — |
| GSK Investigational Site | West Allis | Wisconsin | 53227 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00452699, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 7, 2016 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00452699 live on ClinicalTrials.gov.